CytomX Therapeutics to Present at Multiple Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 /CourierPR/ -- CytomX Therapeutics, a biopharmaceutical company specializing in novel conditionally activated biologics, will present at several upcoming investor conferences in September. Management will participate in the Wells Fargo 21st Annual Healthcare Conference, the 2026 Cantor Global Healthcare Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference.

At the Wells Fargo conference, scheduled for Tuesday, September 8, 2026, at 2:15 p.m. Eastern Time, CytomX will host a fireside chat in Boston, Massachusetts. The 2026 Cantor Global Healthcare Conference, held on Wednesday, September 9, 2026, at 10:20 a.m. Eastern Time, will also feature a CytomX presentation in New York City. The Morgan Stanley conference, taking place on Monday, September 14, 2026, at 1:50 p.m. Eastern Time, will also be hosted in New York.

Attendees will be able to view the live webcast of the presentations on CytomX’s website at www.cytomx.com. Additionally, management will be available for one-on-one meetings with registered investors.

CytomX Therapeutics is dedicated to developing safer and more effective cancer therapies through its PROBODY® platform. The company's pipeline includes several promising candidates, such as Varseta-M (CX-2051), a masked, conditionally activated antibody-drug conjugate (ADC) targeting epithelial cell adhesion molecule (EpCAM) for the treatment of metastatic colorectal cancer. CX-801, a masked interferon alpha-2b PROBODY® cytokine, is also in development for the treatment of metastatic melanoma.

CytomX has established strategic collaborations with leading companies in oncology, including Amgen, Regeneron, and Moderna, to advance its research and development efforts. The company’s vision is to make conditionally activated treatments the new standard of care in the fight against cancer.